Sildenafil
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Hypertension Associated With Connective Tissue Disease
Conditions
Pulmonary Hypertension Associated With Connective Tissue Disease
Trial Timeline
Apr 1, 2013 → Jan 1, 2015
NCT ID
NCT01889966About Sildenafil
Sildenafil is a approved stage product being developed by Pfizer for Pulmonary Hypertension Associated With Connective Tissue Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01889966. Target conditions include Pulmonary Hypertension Associated With Connective Tissue Disease.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Hypertension Associated With Connective Tissue Disease were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01897740 | Pre-clinical | Completed |
| NCT01889966 | Approved | Completed |
| NCT01642407 | Approved | Completed |
| NCT01360671 | Phase 2 | Withdrawn |
| NCT01108900 | Pre-clinical | Completed |
| NCT00800592 | Phase 1 | Completed |
| NCT00666198 | Pre-clinical | Completed |
| NCT00768573 | Pre-clinical | Completed |
| NCT00625079 | Approved | Withdrawn |
| NCT00249730 | Approved | Completed |
| NCT00245596 | Approved | Completed |
| NCT00746967 | Phase 2 | Completed |
| NCT00145483 | Approved | Completed |
| NCT00375297 | Approved | Completed |
Competing Products
20 competing products in Pulmonary Hypertension Associated With Connective Tissue Disease